OTCMKTS:TCNNF - Trulieve Cannabis Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $59.50
  • Forecasted Upside: 20.20 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$49.50
▲ +1 (2.06%)
1 month | 3 months | 12 months
Get New Trulieve Cannabis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TCNNF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TCNNF

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$59.50
▲ +20.20% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Trulieve Cannabis in the last 3 months. The average price target is $59.50, with a high forecast of $107.00 and a low forecast of $23.00. The average price target represents a 20.20% upside from the last price of $49.50.
Buy
The current consensus among 9 polled investment analysts is to buy stock in Trulieve Cannabis.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/10/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/9/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/8/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/6/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/4/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/3/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/1/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/3/2021

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
2/25/2021Stifel NicolausBoost Price TargetBuy$53.00 ➝ $107.00
i
2/4/2021Roth CapitalInitiated CoverageBuy$60.00
i
1/26/2021Alliance Global PartnersBoost Price TargetBuy$66.00
i
1/19/2021Needham & Company LLCBoost Price TargetBuy$36.25 ➝ $60.50
i
1/13/2021Canaccord GenuityBoost Price TargetBuy$60.00 ➝ $75.00
i
11/18/2020Craig HallumBoost Price TargetBuy$45.00 ➝ $50.00
i
11/17/2020Alliance Global PartnersReiterated RatingBuy$40.00 ➝ $50.00
i
11/17/2020Cantor FitzgeraldBoost Price TargetOverweight$60.00 ➝ $63.00
i
Rating by Pablo Zuanic at Cantor Fitzgerald
10/27/2020M PartnersReiterated RatingBuy$31.00
i
9/25/2020Alliance Global PartnersInitiated CoverageBuy
i
9/22/2020Canaccord GenuityBoost Price TargetBuy$45.00 ➝ $51.00
i
9/17/2020Cantor FitzgeraldBoost Price TargetOverweight$59.00 ➝ $60.00
i
Rating by Pablo Zuanic at Cantor Fitzgerald
8/13/2020Cantor FitzgeraldReiterated RatingBuy
i
Rating by Pablo Zuanic at Cantor Fitzgerald
8/4/2020Needham & Company LLCBoost Price TargetBuy$18.20 ➝ $29.25
i
Rating by Matt McGinley at Needham & Company LLC
7/22/2020Stifel NicolausInitiated CoverageBuy
i
6/30/2020Cantor FitzgeraldBoost Price TargetOverweight$50.00 ➝ $52.00
i
5/25/2020Echelon Wealth PartnersReiterated RatingBuy$23.00
i
5/20/2020Needham & Company LLCBoost Price TargetBuy$17.20 ➝ $18.20
i
Rating by Matt McGinley at Needham & Company LLC
5/13/2020Needham & Company LLCBoost Price TargetBuy$15.50 ➝ $17.20
i
Rating by Matt McGinley at Needham & Company LLC
4/8/2020Needham & Company LLCBoost Price TargetBuy$15.25 ➝ $15.50
i
Rating by Matt McGinley at Needham & Company LLC
4/6/2020Cantor FitzgeraldBoost Price TargetOverweight$30.00 ➝ $32.00
i
3/23/2020Needham & Company LLCLower Price TargetBuy$20.00 ➝ $15.25
i
2/13/2020Cantor FitzgeraldInitiated CoverageUnderweight ➝ Overweight$30.00
i
1/22/2020Echelon Wealth PartnersReiterated RatingBuy$21.00
i
12/16/2019Craig HallumInitiated CoverageBuy$20.00
i
12/9/2019Needham & Company LLCReiterated RatingBuy$20.00
i
12/3/2019Needham & Company LLCInitiated CoverageBuy$20.00
i
12/2/2019Compass PointUpgradeNeutral ➝ Buy$11.00 ➝ $17.00
i
Rating by Rommel Dionisio at Compass Point
9/12/2019Compass PointInitiated CoverageHold$9.00
i
(Data available from 3/4/2016 forward)
Trulieve Cannabis logo
Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, California, Massachusetts, and Connecticut, as well as directly to patients through home delivery. It produces approximately 155 stock keeping units, including smokable flower, flower pods for vaporizing, concentrates, topicals, capsules, tinctures, and vape cartridges. As of December 29, 2020, the company operated through 75 dispensaries in the United States. Trulieve Cannabis Corp. is headquartered in Quincy, Florida.
Read More

Today's Range

Now: $49.50
$48.65
$50.25

50 Day Range

MA: $45.31
$39.86
$51.00

52 Week Range

Now: $49.50
$5.74
$53.00

Volume

413,419 shs

Average Volume

518,179 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Trulieve Cannabis?

The following Wall Street sell-side analysts have issued reports on Trulieve Cannabis in the last year: Alliance Global Partners, Canaccord Genuity, Cantor Fitzgerald, Craig Hallum, Echelon Wealth Partners, M Partners, Needham & Company LLC, Roth Capital, and Stifel Nicolaus.
View the latest analyst ratings for TCNNF.

What is the current price target for Trulieve Cannabis?

9 Wall Street analysts have set twelve-month price targets for Trulieve Cannabis in the last year. Their average twelve-month price target is $59.50, suggesting a possible upside of 20.2%. Stifel Nicolaus has the highest price target set, predicting TCNNF will reach $107.00 in the next twelve months. Echelon Wealth Partners has the lowest price target set, forecasting a price of $23.00 for Trulieve Cannabis in the next year.
View the latest price targets for TCNNF.

What is the current consensus analyst rating for Trulieve Cannabis?

Trulieve Cannabis currently has 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TCNNF will outperform the market and that investors should add to their positions of Trulieve Cannabis.
View the latest ratings for TCNNF.

What other companies compete with Trulieve Cannabis?

How do I contact Trulieve Cannabis' investor relations team?

The company's listed phone number is 850-480-7955. The official website for Trulieve Cannabis is www.trulieve.com.